Novo Nordisk's Wegovy now available at Noom for $119 in microdose form

Noom, an online weight-loss company, is offering microdose copies of Novo Nordisk's Wegovy at a starting price of $119, providing a more affordable option for patients. This move aims to make the drug more accessible to those seeking weight loss.

Noom, an online weight-loss company, has introduced a new offering: microdose copies of Novo Nordisk's Wegovy, priced at an introductory rate of $119. This move aims to make the drug more accessible to patients seeking weight loss solutions [1].

Wegovy, a GLP-1 protein-based drug, has shown significant effectiveness in clinical trials, resulting in weight loss of 15% to 20%. However, it is typically priced at around $1,349 per month in the U.S. Novo Nordisk offers a direct-to-consumer cash price of $499 a month for all doses up to 2.4 mg. Noom's new program, in contrast, provides a quarter dose of semaglutide, the generic name for Wegovy, at a lower price point [1].

After the first month, Noom's price for compounded semaglutide rises to $199 a month for a maximum 0.6-milligram dose. This lower dose is intended to reduce side effects and improve patient adherence [1]. Noom's CEO, Geoff Cook, stated that the lower cost and reduced side effects make the product more accessible and affordable for patients [1].

This initiative comes amidst increased competition in the weight-loss drug market. The U.S. Food and Drug Administration (FDA) allowed compounding pharmacies to sell copies of Wegovy during a shortage in 2022, which boosted the demand for such alternatives [1]. However, the FDA has since told compounding pharmacies to end mass sales of these drugs [1].

The introduction of Noom's microdose Wegovy follows a lawsuit filed against Novo Nordisk by investors claiming the company misled them with optimistic growth forecasts and minimized competition risks in the obesity market [2]. The lawsuit alleges that Novo Nordisk's revenue forecast cuts were due to the persistent use of compounded versions of the drug and slower-than-expected market expansion [2].

Noom's new offering presents an alternative to branded Wegovy, potentially attracting patients who seek a more affordable option. However, it remains to be seen how this move will impact the market and Novo Nordisk's competitive position [1].

References:
[1] https://www.reuters.com/business/healthcare-pharmaceuticals/noom-launches-low-dose-compounded-weight-loss-drug-119-2025-08-04/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L1N3TW042:0-wegovy-maker-novo-hit-with-investor-class-action-over-revenue-forecast-cut/